Standout Papers
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (2022)
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis (2012)
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study (2013)
- Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance (2022)
Immediate Impact
11 from Science/Nature 80 standout
Citing Papers
Atopic dermatitis
2025 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Works of Carol A. Connell being referenced
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
2012 Standout
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Carol A. Connell | 2567 | 1258 | 745 | 842 | 39 | 3.7k | |
| Sujatha Menon | 2189 | 1076 | 312 | 1277 | 55 | 3.5k | |
| Terence Rooney | 2781 | 1402 | 830 | 788 | 53 | 3.7k | |
| G Spencer-Green | 2708 | 1069 | 499 | 895 | 39 | 4.0k | |
| Sriram Krishnaswami | 3869 | 2141 | 1227 | 1393 | 59 | 6.0k | |
| Maria Greenwald | 2671 | 1127 | 849 | 1416 | 74 | 5.0k | |
| Eva Baecklund | 2313 | 806 | 1120 | 920 | 75 | 4.8k | |
| Aileen L. Pangan | 3888 | 1941 | 520 | 1935 | 93 | 5.2k | |
| David Gruben | 4337 | 2471 | 1370 | 1464 | 99 | 6.2k | |
| Douglas Schlichting | 2021 | 1039 | 642 | 559 | 32 | 2.7k | |
| Arthur F. Kavanaugh | 2731 | 1226 | 525 | 1024 | 27 | 3.6k |
All Works
Loading papers...